114P Cadonilimab plus chemotherapy as first-line (1L) treatment for metastatic gastric (G) or gastroesophageal junction adenocarcinoma (GEJA) with PD-L1 CPS≤5: Updated results from a real-world study

PD-1 inhibitors plus chemotherapy have been the standard 1L treatment for metastatic G/GEJA, but its efficacy remain poor in patients (pts) with low PD-L1 expression. A phase III study has demonstrated that cadonilimab, a PD-1/CTLA-4 bispecific antibody, showed encouraging activity and manageable safety in previously untreated pts with metastatic G/GEJA, even those with PD-L1 CPS<5. Currently, cadonilimab combined with XELOX as 1L treatment for metastatic G/GEJA was approved by NMPA. Here, we presented the updated efficacy and safety of the combination for metastatic G/GEJA with PD-L1 CPS≤5 in a real-world setting.